Bacteriological and clinical studies on flomoxef in the pediatric field

K. Sunakawa, Y. Ishizuka, N. Kawai, N. Saito, S. Iwata, Y. Sato, H. Akita, S. Kusano, T. Aoki

Research output: Contribution to journalArticle

Abstract

Bacteriological and clinical studies on flomoxef (FMOX, 6315-S) were performed and the results obtained are summarized below. 1. The MIC values of FMOX against 307 clinically isolated strains of Staphylococcus aureus were 0.024 to 100 μg/ml with a peak MIC of 0.39 μg/ml, and the MIC90 value was 1.56 μg/ml. The MIC90 against methicillin resistant S. aureus (MRSA) was 25 μg/ml. 2. FMOX was administered to 15 children with pediatric bacterial infections, and the effectiveness was rated excellent or good in all cases. 3. In bacteriological evaluation, 7 of 11 strains identified prior to the treatment were eliminated (63.6%). 4. As side effects, diarrhea or soft stool was found in 3 cases and eruption in 1 case. As abnormal laboratory values, eosinophilia and thrombocytosis were found in 1 case each. 5. On the intestinal bacterial flora, FMOX had a marked influence just as did other Group 4 and 5 cephems antibiotics. 6. FMOX interfered little with the coagulation system or platelet aggregation.

Original languageEnglish
Pages (from-to)1364-1376
Number of pages13
JournalJapanese Journal of Antibiotics
Volume40
Issue number8
Publication statusPublished - 1987

Fingerprint

Thrombocytosis
Eosinophilia
Methicillin-Resistant Staphylococcus aureus
Platelet Aggregation
Bacterial Infections
Staphylococcus aureus
Diarrhea
Pediatrics
Anti-Bacterial Agents
Therapeutics
Gastrointestinal Microbiome
flomoxef
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Sunakawa, K., Ishizuka, Y., Kawai, N., Saito, N., Iwata, S., Sato, Y., ... Aoki, T. (1987). Bacteriological and clinical studies on flomoxef in the pediatric field. Japanese Journal of Antibiotics, 40(8), 1364-1376.

Bacteriological and clinical studies on flomoxef in the pediatric field. / Sunakawa, K.; Ishizuka, Y.; Kawai, N.; Saito, N.; Iwata, S.; Sato, Y.; Akita, H.; Kusano, S.; Aoki, T.

In: Japanese Journal of Antibiotics, Vol. 40, No. 8, 1987, p. 1364-1376.

Research output: Contribution to journalArticle

Sunakawa, K, Ishizuka, Y, Kawai, N, Saito, N, Iwata, S, Sato, Y, Akita, H, Kusano, S & Aoki, T 1987, 'Bacteriological and clinical studies on flomoxef in the pediatric field', Japanese Journal of Antibiotics, vol. 40, no. 8, pp. 1364-1376.
Sunakawa K, Ishizuka Y, Kawai N, Saito N, Iwata S, Sato Y et al. Bacteriological and clinical studies on flomoxef in the pediatric field. Japanese Journal of Antibiotics. 1987;40(8):1364-1376.
Sunakawa, K. ; Ishizuka, Y. ; Kawai, N. ; Saito, N. ; Iwata, S. ; Sato, Y. ; Akita, H. ; Kusano, S. ; Aoki, T. / Bacteriological and clinical studies on flomoxef in the pediatric field. In: Japanese Journal of Antibiotics. 1987 ; Vol. 40, No. 8. pp. 1364-1376.
@article{3b3c3ae2d0064674878276563c533791,
title = "Bacteriological and clinical studies on flomoxef in the pediatric field",
abstract = "Bacteriological and clinical studies on flomoxef (FMOX, 6315-S) were performed and the results obtained are summarized below. 1. The MIC values of FMOX against 307 clinically isolated strains of Staphylococcus aureus were 0.024 to 100 μg/ml with a peak MIC of 0.39 μg/ml, and the MIC90 value was 1.56 μg/ml. The MIC90 against methicillin resistant S. aureus (MRSA) was 25 μg/ml. 2. FMOX was administered to 15 children with pediatric bacterial infections, and the effectiveness was rated excellent or good in all cases. 3. In bacteriological evaluation, 7 of 11 strains identified prior to the treatment were eliminated (63.6{\%}). 4. As side effects, diarrhea or soft stool was found in 3 cases and eruption in 1 case. As abnormal laboratory values, eosinophilia and thrombocytosis were found in 1 case each. 5. On the intestinal bacterial flora, FMOX had a marked influence just as did other Group 4 and 5 cephems antibiotics. 6. FMOX interfered little with the coagulation system or platelet aggregation.",
author = "K. Sunakawa and Y. Ishizuka and N. Kawai and N. Saito and S. Iwata and Y. Sato and H. Akita and S. Kusano and T. Aoki",
year = "1987",
language = "English",
volume = "40",
pages = "1364--1376",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "8",

}

TY - JOUR

T1 - Bacteriological and clinical studies on flomoxef in the pediatric field

AU - Sunakawa, K.

AU - Ishizuka, Y.

AU - Kawai, N.

AU - Saito, N.

AU - Iwata, S.

AU - Sato, Y.

AU - Akita, H.

AU - Kusano, S.

AU - Aoki, T.

PY - 1987

Y1 - 1987

N2 - Bacteriological and clinical studies on flomoxef (FMOX, 6315-S) were performed and the results obtained are summarized below. 1. The MIC values of FMOX against 307 clinically isolated strains of Staphylococcus aureus were 0.024 to 100 μg/ml with a peak MIC of 0.39 μg/ml, and the MIC90 value was 1.56 μg/ml. The MIC90 against methicillin resistant S. aureus (MRSA) was 25 μg/ml. 2. FMOX was administered to 15 children with pediatric bacterial infections, and the effectiveness was rated excellent or good in all cases. 3. In bacteriological evaluation, 7 of 11 strains identified prior to the treatment were eliminated (63.6%). 4. As side effects, diarrhea or soft stool was found in 3 cases and eruption in 1 case. As abnormal laboratory values, eosinophilia and thrombocytosis were found in 1 case each. 5. On the intestinal bacterial flora, FMOX had a marked influence just as did other Group 4 and 5 cephems antibiotics. 6. FMOX interfered little with the coagulation system or platelet aggregation.

AB - Bacteriological and clinical studies on flomoxef (FMOX, 6315-S) were performed and the results obtained are summarized below. 1. The MIC values of FMOX against 307 clinically isolated strains of Staphylococcus aureus were 0.024 to 100 μg/ml with a peak MIC of 0.39 μg/ml, and the MIC90 value was 1.56 μg/ml. The MIC90 against methicillin resistant S. aureus (MRSA) was 25 μg/ml. 2. FMOX was administered to 15 children with pediatric bacterial infections, and the effectiveness was rated excellent or good in all cases. 3. In bacteriological evaluation, 7 of 11 strains identified prior to the treatment were eliminated (63.6%). 4. As side effects, diarrhea or soft stool was found in 3 cases and eruption in 1 case. As abnormal laboratory values, eosinophilia and thrombocytosis were found in 1 case each. 5. On the intestinal bacterial flora, FMOX had a marked influence just as did other Group 4 and 5 cephems antibiotics. 6. FMOX interfered little with the coagulation system or platelet aggregation.

UR - http://www.scopus.com/inward/record.url?scp=0023190409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023190409&partnerID=8YFLogxK

M3 - Article

C2 - 3430713

AN - SCOPUS:0023190409

VL - 40

SP - 1364

EP - 1376

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 8

ER -